Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sleep disorder19.02.04.0010.001269%Not Available
Sleep terror19.02.03.008; 17.15.02.0060.000846%Not Available
Sluggishness08.01.01.0040.000846%Not Available
Somnolence19.02.05.003; 17.02.04.0060.004230%
Speech disorder19.19.02.002; 17.02.08.003; 22.02.05.0340.002538%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Stress19.06.02.0040.001692%Not Available
Suicidal ideation19.12.01.0030.021995%
Suicide attempt19.12.01.0040.003807%
Swelling08.01.03.0150.001692%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.001269%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.002538%
Tachycardia02.03.02.0070.004230%Not Available
Tardive dyskinesia17.01.02.0120.001269%Not Available
Tearfulness19.15.02.0050.002961%Not Available
Temporomandibular joint syndrome17.14.01.017; 15.01.08.0080.000846%Not Available
Tension19.06.02.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.001692%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Thyroid disorder05.02.01.0020.000846%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.005499%
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.0020.005499%
Urethral disorder20.07.01.002--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.0110.001692%
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0010.003807%
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages